Manuscripts and Publications

Filters: Author is Cooper, Christopher B  [Clear All Filters]
2017
Martinez CH, Diaz AA, Meldrum C, Curtis JL, Cooper CB, Pirozzi C, Kanner RE, Paine R, Woodruff PG, Bleecker ER et al..  2017.  Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS.. Am J Respir Crit Care Med. 195(4):464-472.
Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, C Davis W, Doerschuk CM, Alexis NE, Anderson WH, Henderson AG et al..  2017.  Airway Mucin Concentration as a Marker of Chronic Bronchitis.. N Engl J Med. 377(10):911-922.
Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, R Barr G et al..  2017.  Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(12):956-967.
Han MK, Quibrera PM, Carretta EE, R Barr G, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL et al..  2017.  Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(8):619-626.
Martinez CH, Murray S, R Barr G, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2017.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Ann Am Thorac Soc. 14(5):636-642.
Hansel NN, Paulin LM, Amanda G, Roger P, Alexis NE, Fan V, Bleecker E, Bowler RP, Comellas AP, Dransfield MT et al..  2017.  Subpopulations and Intermediate Outcomes in COPD (SPIROMICS) Air Pollution Study Design. BJM Open Respiratory Research. 4(1)
Anderson WH, Ha JWook, Couper DJ, O'Neal WK, R Barr G, Bleecker ER, Carretta EE, Cooper CB, Doerschuk CM, M Drummond B et al..  2017.  Variability in objective and subjective measures affects baseline values in studies of patients with COPD.. PLoS One. 12(9):e0184606.
2018
Martinez CH, Li SX, Hirzel AJ, Stolberg VR, Alexis NE, R Barr G, Bleecker ER, Carretta EE, Christenson SA, Cooper CB et al..  2018.  Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort.. J Allergy Clin Immunol. 141(1):429-432.
Li X, Ortega VE, Ampleford EJ, R Barr G, Christenson SA, Cooper CB, Couper D, Dransfield MT, Han MLan K, Hansel NN et al..  2018.  Genome-wide association study of lung function and clinical implication in heavy smokers.. BMC Med Genet. 19(1):134.
Pirozzi CS, Gu T, Quibrera PM, Carretta EE, Han MK, Murray S, Cooper CB, Tashkin DP, Kleerup EC, Barjaktarevic I et al..  2018.  Heterogeneous burden of lung disease in smokers with borderline airflow obstruction.. Respir Res. 19(1):223.
Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD, R Barr G, Bleecker E, Cooper CB, Couper D et al..  2018.  Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Respir Res. 19(1):178.
Labaki WW, Xia M, Murray S, Curtis JL, R Barr G, Bhatt SP, Bleecker ER, Hansel NN, Cooper CB, Dransfield MT et al..  2018.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.. Respir Med. 140:87-93.
Paulin LM, Smith BM, Koch A, Han ML, Hoffman EA, Martinez C, Ejike C, Blanc PD, Rous J, R Barr G et al..  2018.  Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort.. Ann Am Thorac Soc. 15(12):1411-1419.
2019
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, R Barr G, Krishnan JA, Lazarus SC et al..  2019.  Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.. Ann Am Thorac Soc. 16(2):200-208.
Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE et al..  2019.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.. Chest. 155(3):519-527.
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Iii RPaine, Bhatt SP, Bhakta NR et al..  2019.  Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.. Int J Chron Obstruct Pulmon Dis. 14:2927-2938.
Arjomandi M, Zeng S, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Cooper CB et al..  2019.  Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS.. Eur Respir J. 54(4)
Labaki WW, Gu T, Murray S, Curtis JL, Yeomans L, Bowler RP, R Barr G, Comellas AP, Hansel NN, Cooper CB et al..  2019.  Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study.. Sci Rep. 9(1):11367.
Garudadri S, Woodruff PG, Han MK, Curtis JL, R Barr G, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G et al..  2019.  Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS.. Chest. 155(5):908-917.

Pages